• Has histologically confirmed new diagnosis of resectable, non-metastatic, squamous cell carcinoma that is either: Stage III Human Papillomavirus (HPV) positive oropharyngeal primary that is tumor size (T) 4, lymph node involvement (N) 0-2, no distant metastases (M0); Stage III or IVA oropharyngeal HPV negative; or Stage III or IVA larynx/hypopharynx/oral cavity primaries.

• Is eligible for primary surgery based on investigator decision and per local practice

• Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 180 days after the last dose of study therapy.

• Male participants must refrain from donating sperm throughout the study period and for up to 180 days after the last dose of study therapy

• Female participant that is not pregnant or breastfeeding

• Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI), based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

• Has provided newly obtained core or excisional biopsy of a tumor lesion not previously irradiated

• Has results from testing of HPV status for oropharyngeal cancer defined as p16

• Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 10 days of randomization